Lind Joanne M, Chiu Christine, Semsarian Christopher
University of Sydney, Faculty of Medicine, Agnes Ginges Centre for Molecular Cardiology, Centenary Institute, Locked Bag No. 6, Newtown, NSW 2042, Australia.
Expert Rev Cardiovasc Ther. 2006 Nov;4(6):927-34. doi: 10.1586/14779072.4.6.927.
Hypertrophic cardiomyopathy (HCM) was the first cardiovascular disorder in which a genetic basis was identified. The disease is characterized by a marked thickening of the left ventricle and is the most common structural cause of sudden cardiac death in those aged under 35 years. HCM is primarily a disease of the sarcomere with over 250 mutations identified currently within 13 sarcomere-related genes. At present, genetic screening is available for the genes shown to cause HCM most frequently, with a mutation pick-up rate of up to 60%. Current research is focused on the identification of additional causative genes and elucidation into signaling mechanisms involved in HCM pathogenesis, as well as investigation of modifying factors that can alter the clinical phenotype in HCM. The unifying goal of these studies is to improve our understanding of disease pathogenesis in HCM, thereby facilitating the process of new diagnostic and therapeutic approaches in patients, ultimately leading to disease prevention and possible curative treatment.
肥厚型心肌病(HCM)是首个确定有遗传基础的心血管疾病。该疾病的特征是左心室显著增厚,是35岁以下人群心脏性猝死最常见的结构性病因。HCM主要是一种肌节疾病,目前已在13个与肌节相关的基因中鉴定出250多种突变。目前,针对最常导致HCM的基因可进行基因筛查,突变检出率高达60%。当前的研究重点是识别其他致病基因,阐明HCM发病机制中涉及的信号传导机制,以及研究可改变HCM临床表型的修饰因素。这些研究的共同目标是增进我们对HCM疾病发病机制的理解,从而推动针对患者的新诊断和治疗方法的进程,最终实现疾病预防和可能的治愈性治疗。